Nasdaq

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin ...

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Hosted on MSN

Intellia Therapeutics’ stock rocked by patient death in gene therapy trial

A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse event (AE). The patient had been dosed with nex-z (nexiguran ziclumeran) in ...
Nasdaq

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Hosted on MSN

Intellia Therapeutics stock gains — FDA lifts clinical hold on pivotal trial

Intellia Therapeutics Inc. NTLA shares are up on Monday following the FDA’s decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial. The FDA imposed clinical holds on the INDs for ...